Alzheimer's Disease Neuroimaging Initiative 2

Conditions

Alzheimer's Disease | Mild Cognitive Impairment (MCI)

What is the purpose of this trial?

The purpose of this study is to build upon the information obtained in the original Alzheimer's Disease Neuroimaging Initiative (ADNI1) and ADNI-GO (Grand Opportunity; a study funded through an NIH grant under the American Recovery and Reinvestment Act), to examine how brain imaging technology can be used with other tests to measure the progression of mild cognitive impairment (MCI) and early Alzheimer's disease (AD). ADNI2 seeks to inform the neuroscience of AD. This information will aid in the early detection of AD, and in measuring the effectiveness of treatments in future clinical trials.



Participation Guidelines

Age:
55 Years - 90 Years
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
Alzheimer's Disease Cooperative Study (ADCS)
National Institute on Aging (NIA)
Northern California Institute of Research and Education
Dates:
January 2011
Last Updated:
September 15, 2014
Study HIC#:

Clinicaltrials.gov ID: NCT01231971